The Drug Diversion Triad

Maureen Burger, Chief Nursing Officer, Visante.

2021-10-12

  • Identify one change in DEA rules due to COVID-19

  • Describe at least two workflow changes during COVID-19 that created unintended opportunities for diversion

  • Relate human responses to COVID-19 and impact on rate of drug diversion in healthcare

  • Evaluate three drug diversion risk mitigation strategies

This document is only available to subscribers